Astellas Buys Amevive From Biogen Idec
This article was originally published in The Pink Sheet Daily
Executive Summary
Astellas will purchase Biogen Idec's psoriasis biologic Amevive (alefacept) for $60 mil. plus royalties
You may also be interested in...
Astellas Advances Alefacept To Phase II For Renal Transplant Rejection Prevention
Taking a step to expand its immunosuppressant pipeline, Astellas is initiating Phase II clinical trials in North America and Europe for its biologic ASP0485 (alefacept) to prevent renal transplant rejection, the firm announced Sept. 12
Astellas Advances Alefacept To Phase II For Renal Transplant Rejection Prevention
Firm will test the biologic as an adjunct to its immunosuppressant Prograf, which has a different mechanism of action.
Astellas Advances Alefacept To Phase II For Renal Transplant Rejection Prevention
Firm will test the biologic as an adjunct to its immunosuppressant Prograf, which has a different mechanism of action.